logo
  • About
    • About VGXI
    • Leadership
    • VGXI Mission
    • Awards
    • FAQ
    • Careers
  • Services
    • Manufacturing Services
    • cGMP Plasmid
    • HD Plasmid
    • Pre-Clinical Plasmid
    • Additional Services
  • VGXI Process
    • VGXI Manufacturing Process
    • Analytical Testing
    • Quality Systems
  • News and Events
    • News
    • Events
  • Contact Us

Recent News

VGXI Official Statement Regarding COVID-19

April 17, 2020

A Message from VGXI Regarding the Coronavirus (COVID-19) Outbreak and VGXI Actions LAST UPDATED January 15, 2021 To our Valued Clients and Business Partners, VGXI recognizes your concerns regarding the potential impact of the coronavirus outbreak on our products and services. VGXI is actively monitoring the situation and will continue to provide… Read More »

VGX Pharmaceuticals Announces Initiation of VGX-cGMP Manufactured Plasmid Products in Clinical Use by Partners

February 5, 2008

VGX Pharmaceuticals today announced that the DNA plasmid-based product manufactured by VGX on behalf of Nucleonics,Inc. has entered Phase I human clinical trials in the United States and Europe for the treatment of chronic Hepatitis B virus (HBV) infection. The Nucleonics’ HBV clinical candidate (NUC B1000) is an expressed interfering RNA (eiRNA)… Read More »

VGX Animal Health announces approval of LifeTide™ SW 5 – World’s First and Only Approved DNA Therapy for Food Animals

January 9, 2008

VGX Animal Health, Inc. (VGXAH), a developer of cutting edge technologies for animal health applications, announced today the approval by the Australian Pesticides and Veterinary Medicines Authority (APVMA) of LifeTide™ SW 5, the Company’s leading Growth Hormone Releasing Hormone (GHRH) product for swine therapy. LifeTide™ SW 5 is an injectable DNA plasmid… Read More »

VGX Pharmaceuticals announces an agreement with VGX International to build a large scale cGMP DNA manufacturing plant in Korea

October 29, 2007

VGX Pharmaceuticals, Inc., a leading developer of novel drugs and vaccines, announced today that it has signed a collaboration and license agreement with VGX International, Inc. The Agreement provides the technical support and manufacturing process technology necessary for VGX International to construct and operate a large-scale cGMP, DNA plasmid manufacturing facility in… Read More »

VGX Pharmaceuticals adds cGMP plasmid DNA manufacturing capacity

October 24, 2007

VGX Pharmaceuticals, Inc., a leading manufacturer of cGMP-grade DNA plasmids, announced today that it has expanded its manufacturing capacity with the installation and testing of a new 500-liter scale fermentor in its cGMP manufacturing facility in The Woodlands, Texas. The new fermentor gives VGX significantly more flexibility than its current 100-liter production… Read More »

VGX Pharmaceuticals Announces Issuance of Two Key U.S. Patents Covering DNA Plasmid Manufacturing Technology and the Treatment of Anemia

July 7, 2007

VGX Pharmaceuticals today announced that it has been granted U.S. Patent number 7,238,522 covering its DNA plasmid manufacturing technology. The patent entitled, “Device and Methods for Biomaterial Production” represents the first to issue of a series of applications related to VGX’s novel approach to DNA plasmid manufacturing. “We are very pleased to… Read More »

  • « Previous
  • 1
  • …
  • 15
  • 16
  • 17
View More

Sign Up

For more information

Archives

  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007

Get In Touch

We would like to hear from you. Contact us today to ask a question or request a quote for our plasmid DNA manufacturing services.

CONTACT US


logo

VGXI, INC.

2700 Research Forest Drive, Suite 180, The Woodlands, Texas 77381, USA

281-296-7300

© 2020 VGXI, Inc. All Rights Reserved. | Terms and Conditions | Privacy Policy | Resources | Careers